World Asset Management Inc decreased its stake in Sanofi SA (NYSE:SNY) by 15.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,496 shares of the company’s stock after selling 8,643 shares during the period. World Asset Management Inc’s holdings in Sanofi were worth $2,166,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in SNY. Private Capital Group LLC lifted its position in Sanofi by 271.3% in the first quarter. Private Capital Group LLC now owns 2,577 shares of the company’s stock worth $103,000 after purchasing an additional 1,883 shares during the period. Squar Milner Financial Services LLC bought a new position in Sanofi in the second quarter worth $169,000. New England Research & Management Inc. bought a new position in Sanofi in the third quarter worth $205,000. We Are One Seven LLC bought a new position in Sanofi in the third quarter worth $227,000. Finally, Natixis bought a new position in Sanofi in the second quarter worth $213,000. Institutional investors and hedge funds own 7.54% of the company’s stock.
Shares of NYSE SNY opened at $42.89 on Friday. The firm has a market cap of $112.04 billion, a price-to-earnings ratio of 13.70, a P/E/G ratio of 2.40 and a beta of 0.82. Sanofi SA has a 52-week low of $37.43 and a 52-week high of $50.04. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85.
Sanofi (NYSE:SNY) last issued its quarterly earnings data on Tuesday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.72 by $0.02. The company had revenue of $8.18 billion during the quarter, compared to analysts’ expectations of $8.27 billion. Sanofi had a return on equity of 23.77% and a net margin of 10.29%. The business’s revenue was down 5.6% on a year-over-year basis. During the same period last year, the business earned $1.35 earnings per share. As a group, sell-side analysts predict that Sanofi SA will post 3.14 earnings per share for the current year.
In other Sanofi news, major shareholder Sanofi sold 104,552 shares of Sanofi stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.00% of the stock is currently owned by company insiders.
Several brokerages recently commented on SNY. Citigroup raised Sanofi from a “neutral” rating to a “buy” rating in a research report on Friday, August 10th. Bank of America raised Sanofi from a “neutral” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Monday, September 10th. Zacks Investment Research raised Sanofi from a “sell” rating to a “hold” rating in a report on Tuesday, August 28th. Deutsche Bank reissued a “buy” rating on shares of Sanofi in a report on Wednesday, August 1st. Finally, BNP Paribas raised Sanofi from a “neutral” rating to an “outperform” rating in a report on Wednesday, August 1st. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the stock. Sanofi has a consensus rating of “Hold” and an average price target of $49.00.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Further Reading: The Role of a Fiduciary and Individual Investors
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.